Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Japan has granted the first approval worldwide for brodalumab as a biologic therapy for psoriasis, one of two new antibodies for the disorder in a new batch of approvals that also includes Praluent and Kyprolis.

With a gap in endometriosis treatments on the market, Citeline analyst Benjamin Graham looks at the pipeline to see what those suffering can expect in the coming years.

Japan has granted reimbursement prices to a batch of new drugs, including a new therapy for hepatitis C, a novel anticoagulant and a new insomnia treatment.